DV
Dividend Vision

TELO — Telomir Pharmaceuticals, Inc. Common Stock

Telomir Pharmaceuticals, Inc. Common Stock (TELO)

Total return is -84.4% over the past 2.5 years, 145.0 points behind SPY at 60.6%. Its deepest 1-year drawdown was 52.4%.

Telomir Pharmaceuticals is a preclinical-stage biotechnology company developing small-molecule therapeutics targeting upstream biological drivers of aging and age-related diseases, with its lead program Telomir-1 in development for conditions including Wilson's disease, Type 2 diabetes, age-related macular degeneration, Alzheimer's disease, and oncology. The company does not currently distribute dividends. This security appeals to investors with a high risk tolerance seeking exposure to early-stage biotechnology development.

TELO key facts

Asset type
Stock
Asset class
Equity
Inception date
02/07/2024
Last close
$1.09
Market cap
$74,276,960
Average volume
53400.0
Beta
-0.244
Payout ratio
0.0
Forward P/E
0.0
EPS
$-0.34